Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) Short Interest Up 247.4% in June

Chemomab Therapeutics Ltd. Sponsored ADR (NASDAQ:CMMB) was the recipient of a large increase in short interest in the month of June. As of June 15th, there was short interest totaling 134,275 shares, an increase of 247.4% from the May 31st total of 38,648 shares. Based on an average daily volume of 49,633 shares, the short-interest ratio is currently 2.7 days. Approximately 2.1% of the shares of the company are short sold.

Analyst Ratings Changes

Separately, Weiss Ratings reaffirmed a “sell (e+)” rating on shares of Chemomab Therapeutics in a report on Friday, May 8th. One equities research analyst has rated the stock with a Buy rating, one has given a Hold rating and one has issued a Sell rating to the stock. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus price target of $25.00.

Chemomab Therapeutics Price Performance

Shares of CMMB stock traded up $0.03 on Monday, reaching $1.62. 11,457 shares of the stock were exchanged, compared to its average volume of 59,610. Chemomab Therapeutics has a one year low of $1.35 and a one year high of $4.92. The stock has a market cap of $11.66 million, a PE ratio of -0.73 and a beta of 0.62. The stock has a 50 day moving average price of $1.70 and a 200 day moving average price of $1.74.

Chemomab Therapeutics (NASDAQ:CMMB) last issued its quarterly earnings data on Thursday, May 14th. The company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.04) by ($0.18). On average, research analysts expect that Chemomab Therapeutics will post -0.4 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Chemomab Therapeutics

Hedge funds have recently added to or reduced their stakes in the business. Kestra Private Wealth Services LLC lifted its holdings in shares of Chemomab Therapeutics by 19.3% during the first quarter. Kestra Private Wealth Services LLC now owns 61,710 shares of the company’s stock worth $97,000 after buying an additional 10,000 shares in the last quarter. XTX Topco Ltd bought a new stake in Chemomab Therapeutics during the fourth quarter worth about $31,000. Finally, ADAR1 Capital Management LLC acquired a new stake in Chemomab Therapeutics during the fourth quarter worth about $132,000. Institutional investors and hedge funds own 46.05% of the company’s stock.

Chemomab Therapeutics Company Profile

Chemomab Therapeutics (NASDAQ:CMMB) is a clinical-stage biopharmaceutical company focused on the discovery, development and commercialization of next-generation antibody therapies. The company leverages a proprietary antibody engineering platform to generate novel bi- and multi-specific antibodies with applications in oncology, infectious diseases and inflammatory disorders. By combining cutting-edge discovery tools with translational research, Chemomab aims to advance promising candidates from early proof-of-concept through clinical development.

Among its pipeline programs, Chemomab is advancing antibody candidates designed to target key tumor antigens and pathogen-specific epitopes.